Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22081624 | 0.89 | GABRA1 (0.41) | GABRA1GABRB2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL16955330 | 0.89 | GABRA1 (0.46) | GABRA1GABRB2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL464374 | 0.86 | CA12 (0.54) | SMN1; SMN2KDM4EALDH1A1MAPK1MAPT | |
| SCHEMBL13344106 | 0.86 | GABRA1 (0.43) | GABRA1GABRB2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12884485 | 0.85 | GABRA1 (0.48) | GABRA1GABRB2ALDH1A1HPGDADRA2A | |
| SCHEMBL23536830 | 0.84 | GABRA1 (0.52) | GABRA1GABRB2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12648278 | 0.84 | SLC6A2 (0.43) | GABRA1GABRB2ALDH1A1MAPK1MAPT | |
| SCHEMBL300777 | 0.84 | CA1 (0.53) | GABRA1GABRB2KDM4EALDH1A1MAPK1 | |
| SCHEMBL16956553 | 0.84 | GABRA1 (0.41) | GABRA1GABRB2SMN1; SMN2KDM4EALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7313508 | 0.84 | CA12 (0.53) | SMN1; SMN2KDM4EALDH1A1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5475155-A | Reacting an alpha-haloketone with a phenolic-hydroxyl containing compound and a strong protonic acid; neutralization; dehydrohalogenation; dealkylation | THE DOW CHEMICAL COMPANY (US) | 1995-12-12 | — | — | US | claimed |
| WO-1995015301-A1 | PREPARATION OF 4,4'-DIHYDROXY-ALPHA-ALKYLSTILBENES AND 4,4'-DIHYDROXY-ALPHA, ALPHA'-DIALKYLSTILBENES | THE DOW CHEMICAL COMPANY (US) | 1995-06-08 | — | — | WO | claimed |
| US-11840601-B2 | Composition of alkoxysilyl-functionalized epoxy resin and composite thereof | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2023-12-12 | — | — | US | disclosed |
| EP-2616513-B1 | CATALYSTS AND METHODS FOR POLYMER SYNTHESIS | SAUDI ARAMCO TECH CO (SA) | 2019-11-06 | — | — | EP | disclosed |
| US-20170066789-A1 | NOVEL EPOXY COMPOUND, MIXTURE, COMPOSITION, AND CURED PRODUCT COMPRISING SAME, METHOD FOR PREPARING SAME, AND USE THEREOF | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2017-03-09 | — | — | US | disclosed |
| CN-103097364-B | Spiro-piperidine derivatives as S1P modulators | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2015-11-25 | — | — | CN | disclosed |
| CN-103097364-A | Spiro-piperidine derivatives as S1P modulators | ABBOTT HEALTHCARE PRODUCTS BV | 2013-05-08 | — | — | CN | disclosed |
| US-20100112619-A1 | LIGAND-CONTAINING MICELLES AND USES THEREOF | GRAHAM RONALD J | 2010-05-06 | — | — | US | disclosed |
| EP-0929506-A1 | PROCESS FOR PREPARING STILBENE DIOLS | THE DOW CHEMICAL COMPANY (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0927149-A1 | PROCESS FOR PREPARING AND RECOVERING 4,4'-DIHYDROXY-ALPHA-ALKYLSTILBENE OR 4,4'-DIHYDROXY-ALPHA, ALPHA'-DIALKYLSTILBENE | THE DOW CHEMICAL COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998011043-A1 | PROCESS FOR PREPARING STILBENE DIOLS | THE DOW CHEMICAL COMPANY (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998011044-A1 | PROCESS FOR PREPARING AND RECOVERING 4,4'-DIHYDROXY-ALPHA-ALKYLSTILBENE OR 4,4'-DIHYDROXY-ALPHA, ALPHA'-DIALKYLSTILBENE | THE DOW CHEMICAL COMPANY (US) | 1998-03-19 | — | — | WO | disclosed |
| US-5723693-A | Process for preparing and recovering 4,4'-dihydroxy-alpha-alkylstilbene or 4,4'-dihydroxy-alpha, alpha'dialkylstilbene | THE DOW CHEMICAL COMPANY (US) | 1998-03-03 | — | — | US | disclosed |
| US-5475155-A | Reacting an alpha-haloketone with a phenolic-hydroxyl containing compound and a strong protonic acid; neutralization; dehydrohalogenation; dealkylation | THE DOW CHEMICAL COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995015301-A1 | PREPARATION OF 4,4'-DIHYDROXY-ALPHA-ALKYLSTILBENES AND 4,4'-DIHYDROXY-ALPHA, ALPHA'-DIALKYLSTILBENES | THE DOW CHEMICAL COMPANY (US) | 1995-06-08 | — | — | WO | disclosed |
| US-5414150-A | Preparation of 4,4'-dihydroxy-alpha-alkylstilbenes and 4,4'-dihydroxy-alpha, alpha'-dialkylstilbenes | THE DOW CHEMICAL COMPANY (US) | 1995-05-09 | — | — | US | disclosed |
| EP-0173279-B1 | 2-(3,5-DIALKYL-4-HYDROXYPHENYL)INDOLE DERIVATIVES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1989-08-23 | — | — | EP | disclosed |
| US-4695581-A | LIPOXYGENASE INHIBITOR | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1987-09-22 | — | — | US | disclosed |
| EP-0173279-A1 | 2-(3,5-Dialkyl-4-hydroxyphenyl)indole derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1986-03-05 | — | — | EP | disclosed |
| US-4538003-A | TREATMENT WITH MAGNESIUM OR ZINC ORGANOMETALLIC REAGENTS IN PRESENE OF A NICKEL BIDENTATE OR TRIDENTATE PHOSPHOROUS LIGAND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066789-A1 | NOVEL EPOXY COMPOUND, MIXTURE, COMPOSITION, AND CURED PRODUCT COMPRISING SAME, METHOD FOR PREPARING SAME, AND USE THEREOF | ESD, NOTUM, PFAS | GABRA1 3432/4885GABRB2 4049/4885SMN1; SMN2 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.